HomeTrending StocksWhat’s Driving The Lipocine Inc. (LPCN) Stock Higher Pre-Market Today?

What’s Driving The Lipocine Inc. (LPCN) Stock Higher Pre-Market Today?

Shares of biopharmaceutical company Lipocine Inc. (NASDAQ: LPCN) have been up trending in early hours trading today. As of 07:17 a.m. EST, the stock was up +9.79% to $1.57 with 1.16M shares changed hands.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What’s driving the stock?


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Biopharmaceutical company Lipocine Inc. focuses on the development of pharmaceutical products for metabolic disorders and endocrinological disorders. Primarily, it is focused on developing oral delivery systems for pharmaceuticals with poor bioavailability. A portfolio of product candidates provided by the company aims to produce pharmacokinetics that produces lower dosing requirements, circumvent first-pass metabolic pathways in certain places, reduce side effects, and decrease the negative effects following gastro-intestinal interaction.

Read More

There are five clinical development pipeline products for Lipocine. They are ORLANDO, LPCN 1144, ORLANDO XR, LPCN 1148, and LPCN 1107. The novel oral testosterone prodrug ORLANDO contains testosterone undecanoate. The FDA has tentatively approved the prodrug for conditions associated with a deficiency of endogenous testosterone in male adults, also referred to as hypogonadism.

Lipocine is scheduled to present the clinical data for ORLANDO at the ENDO 2021 Conference, to take place March 20-23, 2021, the company announced recently.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

A public offering of shares of Lipocine’s common stock was closed by Lipocine during the last month offering 16,428,571 shares. Upon the public offering of the common stock, the underwriters exercised in full their option to purchase 2,142,857 additional shares of common stock at the public offering price. Before deducting underwriting discounts and commissions or other expenses payable by Lipocine, the gross proceeds to the company were approximately $28.7 million.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam